Unigene Accelerates Development of Anorexigenic Peptide

Published:March 6th, 2011

Unigene Laboratories has announced it is accelerating the development of its proprietary anorexigenic peptide UGP281. The anorexigenic peptide can diminish or control appetite. Unigene expects to initiate Phase 1 clinical studies in the first half of 2012. The acceleration of the development of UGP281 has the potential to address an important medical need.

The lead satiety compound from Unigene, UGP281 has already demonstrated substantial decreases in food consumption in preclinical studies. Most peptides on the market require injection and there are no oral peptide therapeutic products as oral delivery has been hindered by low absorption and degradation in the gastro-intestinal tract.

Larger peptides are difficult to produce through synthetic routes and chemical synthesis has been associated with higher impurity. Unigene is focusing on relatively large peptides and has developed a proprietary E. coli expression system that has advantages over chemical synthesis. Unigene’s core competence, Peptelligence will allow manufacturing of UGP281 by Unigene’s proprietary recombinant production and oral delivery technologies. Competitors rely on drugs that rely on injectable, depot or patch formulas.


Write a Comment of Unigene Accelerates Development of Anorexigenic Peptide



Page copy protected against web site content infringement by Copyscape